Is Von Hippel-Lindau Disease hereditary?

Von Hippel-Lindau (VHL) disease is a hereditary condition, meaning it is caused by a genetic mutation that is passed from parent to child. It follows an autosomal dominant inheritance pattern, which means an individual only needs one copy of the mutated VHL gene to develop the disease, resulting in a 50% chance of passing the condition to each offspring.

Is Von Hippel-Lindau disease strictly hereditary?

Von Hippel-Lindau disease is both genetic and hereditary. It is "genetic" because it is caused by a pathogenic variant (mutation) in the VHL tumor suppressor gene located on chromosome 3. It is "hereditary" because this mutation can be inherited from an affected parent. While most cases are inherited, approximately 20% of individuals with Von Hippel-Lindau disease have the condition due to a de novo (spontaneous) mutation that occurred for the first time in their own genetic material, meaning neither parent carries the mutation.

What is the inheritance pattern of Von Hippel-Lindau disease?

Von Hippel-Lindau disease follows an autosomal dominant inheritance pattern. In this pattern, the presence of a single mutated copy of the VHL gene is sufficient to cause the disease, even if the other copy of the gene is normal. Because the gene is located on an autosome (not a sex chromosome), both males and females are affected with equal frequency and can pass the condition to their children. If a parent has Von Hippel-Lindau disease, each child has a 50% statistical probability of inheriting the mutation.

How is genetic testing and counseling utilized for Von Hippel-Lindau disease?

Genetic testing is the gold standard for confirming a diagnosis of Von Hippel-Lindau disease. Molecular genetic testing, typically involving sequencing of the VHL gene, can identify the specific mutation in approximately 95% to 99% of affected individuals. Genetic counseling is strongly recommended for anyone diagnosed with Von Hippel-Lindau disease or those with a family history of the condition to help families understand the following:

• Risk Assessment: Understanding the 50% recurrence risk for future children.


• Family Screening: Identifying at-risk family members who may require early surveillance for tumors.


• Reproductive Options: Discussing prenatal diagnosis or preimplantation genetic testing (PGT) for those wishing to conceive.


• De Novo Mutation Clarification: Determining if the mutation is inherited or a new occurrence, which changes the risk profile for other family members.

Why is early identification important for families?

Because Von Hippel-Lindau disease involves a predisposition to developing various benign and malignant tumors—such as hemangioblastomas, renal cell carcinomas, and pheochromocytomas—early genetic identification is vital. At DiseaseMaps.org, 100 members of our community have shared their experiences, underscoring that proactive genetic knowledge allows for earlier clinical surveillance, which significantly improves outcomes for those living with Von Hippel-Lindau disease.

Next steps

• Consult with a clinical geneticist or a genetic counselor to discuss your family history and testing options.


• If you have been diagnosed, ensure your first-degree relatives are informed about the inheritance risks and the need for genetic counseling.


• Connect with the DiseaseMaps.org community to share experiences and find resources for managing the complexities of Von Hippel-Lindau disease.


• Request a referral to a VHL-specialized center for comprehensive, multidisciplinary clinical surveillance.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• National Institutes of Health (NIH) - Genetic and Rare Diseases Information Center (GARD): Von Hippel-Lindau disease.


• Orphanet: Von Hippel-Lindau disease (ORPHA:908).


• Online Mendelian Inheritance in Man (OMIM): Von Hippel-Lindau Syndrome (#193300).


• VHL Alliance: Official patient support and clinical resources for Von Hippel-Lindau disease.